Azacitidine: A review of its use in higher-risk myelodysplastic syndromes acute myeloid leukaemia

Drugs

Volumn 69, Issue 17, 2009, Pages 2501-2518

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMINOCAPROIC ACID; ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; AZACITIDINE; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IDARUBICIN; IRON CHELATING AGENT; LENALIDOMIDE; MITOXANTRONE; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; BACTERIAL INFECTION; BLAST CELL; BLEEDING; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOGENETICS; DIARRHEA; DISEASE COURSE; DNA METHYLATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; HIGH RISK PATIENT; HUMAN; INFECTION; INJECTION SITE REACTION; IRON OVERLOAD; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; REVIEW; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BONE MARROW; BONE MARROW CELLS; CHROMOSOME INVERSION; COMBINED MODALITY THERAPY; ERYTHROCYTE TRANSFUSION; ERYTHROID PRECURSOR CELLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 72049122920     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11202840-000000000-00000     Document Type: Review

References (72)

1. Nimer SD. Myelodysplastic syndromes. Blood 2008 May 15; 111 (10): 4841-4851
2. Jadersten M, Hellstrom-Lindberg E. Myelodysplastic syndromes: biology and treatment. J Intern Med 2009 Mar; 265 (3): 307-328
3. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982 Jun; 51 (2): 189-199
4. Brunning R, Orazi A, Germing U, et al. Myelodysplastic syndromes. In: Swerdlow S, Campo E, Harris NL, et al, editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissue. 4th ed. Lyon: IARC Press, 2008: 88-103
5. Stone RM. How I treat patients with myelodysplastic syndromes. Blood 2009 Jun 18; 113 (25): 6296-6303
6. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: myelodysplastic syndromes: v.1.2010 [online]. Available from URL: http://www. nccn.org/professionals/physician-gls/PDF/mds.pdf [Accessed 2009 Aug 19]
7. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997 Mar 15; 89 (6): 2079-2088
8. European Medicines Agency. Summary of product characteristics: azacitidine [online]. Available from URL: http:// www.emea.europa.eu/humandocs/ PDFs/EPAR/vidaza/H-978-PI-en.pdf [Accessed 2009 Jul 29]
9. Boehrer S, Ades L, Tajeddines N, et al. The capacity of the hypomethylating agents azacytidine and decitabine to induce apoptosis and cell cycle arrest depends on the activation of the DNA-damage response pathway [abstract no. 1655]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6-9; San Francisco (CA)
10. Herman JG, Gore SD, Mufti GJ, et al. Relationship among gene methylation, azacitidine treatment, and survival in patients with higher-risk myelodysplastic synrdomes (MDS): results from the AZA-001 trial [abstract no. 4746]. 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver (CO)
11. Martin MG, Walgren R, Procknow E, et al. Azacitidine-induced changes in the MDS methylome are associated with clinical responses [abstract no. 2691]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6-9; San Francisco (CA)
12. Glover AB, Leyland-Jones B. Biochemistry of azacitidine: a review. Cancer Treat Rep 1987 Oct; 71 (10): 959-964
13. Leone G, Teofili L, Voso MT, et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002 Dec; 87 (12): 1324-1341
14. Qin T, Jelinek J, Si J, et al. Mechanisms of resistance to 5-aza-20-deoxycytidine in human cancer cell lines. Blood 2009 Jan 15; 113 (3): 659-667
15. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001 Apr 3; 134 (7): 573-586
16. Murakami T, Li X, Gong J, et al. Induction of apoptosis by 5-azacytidine: drug concentration-dependent differences in cell cycle specificity. Cancer Res 1995 Jul 15; 55 (14): 3093-3098
17. Khan R, Schmidt-Mende J, Karimi M, et al. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol 2008 Feb; 36 (2): 149-157
18. Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009 Oct 15; 114 (16): 3448-3458
19. Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15INK4b gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998 Apr 15; 91 (8): 2985-2990
20. Jiang Y, Dunbar A, Gondek LP. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009 Feb 5; 113 (6): 1315-1325
21. Christman JK, Mendelsohn N, Herzog D, et al. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60). Cancer Res 1983 Feb; 43 (2): 763-769
22. Abdulhaq H, Rossetti JM. The role of azacitidine in the treatment of myelodysplastic syndromes. Expert Opin In-vestig Drugs 2007 Dec; 16 (12): 1967-1975
23. Momparler RL, Momparler LF, Samson J. Comparison of the antileukemic activity of 5-AZA-20-deoxycytidine, 1-b-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk Res 1984; 8 (6): 1043-1049
24. Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebular-ine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009 Jun; 23 (6): 1019-1028
25. Raj K, John A, Ho A, et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007 Sep; 21 (9): 1937-1944
26. Fandy TE, Herman JG, Kerns P. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009 Sep 24; 114 (13): 2764-2773
27. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009 Mar; 10 (3): 223-232
28. Visvader J, Adams JM. Megakaryocytic differentiation induced in 416B myeloid cells by GATA-2 and GATA-3 transgenes or 5-azacytidine is tightly coupled to GATA-1 expression. Blood 1993 Sep 1; 82 (5): 1493-1501
29. Zinzar S, Silverman LR, Richardson EB, et al. Azacytidine plus verapamil induces the differentiation of a newly characterized biphenotypic human myeloid-B lymphoid leukemic cell line BW-90. Leuk Res 1998 Aug; 22 (8): 677-685
30. Lopez-Karpovitch X, Barrales-Benitez O, Flores M, et al. Effect of azacytidine in the release of leukemia inhibitory factor, oncostatin M, interleukin (IL)-6, and IL-11 by mononuclear cells of patients with refractory anemia. Cytokine 2002 Nov 24; 20 (4): 154-162
31. Marcucci G, Silverman L, Eller M, et al. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 2005 May; 45 (5): 597-602
32. Rudek MA, Zhao M, He P, et al. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 2005 Jun 10; 23 (17): 3906-3911
33. Israili ZH, Vogler WR, Mingioli ES, et al. The disposition and pharmacokinetics in humans of 5-azacytidine administered intravenously as a bolus or by continuous infusion. Cancer Res 1976 Apr; 36 (4): 1453-1461
34. Silverman LR, Holland JF, Demakos EP, et al. Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921 [abstract no. 46]. Ann Hematol 1994; 68: A12
35. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002 May 15; 20 (10): 2429-2440
36. Food and Drug Administration. Center for Drug Evaluation and Research approval package for application number 50-794: clinical pharmacology and biopharmaceutics review [online]. Available from URL: http://www.access data.fda.gov/drugsatfda-docs/nda/2004/50-794-Vidaza- BioPharmr.pdf [Accessed 2009 Oct 1]
37. European Medicines Agency. Assessment report for Vidaza (azacitidine) [online]. Available from URL: http://www. emea.europa.eu/humandocs/PDFs/EPAR/ vidaza/H-978-en6. pdf [Accessed 2009 Jul 29]
38. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelo-dysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006 Aug 20; 24 (24): 3895-3903
39. Silverman LR, McKenzie DR, Peterson BL, et al. Analysis of survival, AML transformation, and transfusion independence in patients with high-risk myelodysplastic syndromes (MDS) receiving azacitidine determined using a prognostic model [abstract no. 2523 plus poster]. 47th Annual Meeting and Exposition of the American Society of Hematology; 2005 Dec 10-13; Atlanta (GA)
40. Sebert M, Hernandez E, Chermat F, et al. Treatment of high risk MDS and AML post-MDS with azacytidine (AZA): current results of the French ATU program [abstract no. 0428]. Haematologica 2007 Jun 1; 92 Suppl. 1: 158-159
41. Fabre C, Gardin C, Mbida R-M, et al. Treatment of AML with azacytidine (AZA): current results of the French ATU program [abstract no. 1849]. Blood 2007 Nov 16; 110 (11 Pt 1): 547-548
42. Itzykson R, Thepot S, Fabre C, et al. Response to azacytidine (AZA) in MDS or AML with Del 5q: current results of the French ATU program [abstract no. 2682]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6-9; San Francisco (CA)
43. Maurillo L, Spagnoli A, Gozzini A, et al. 5-azacytidine for the treatment of intermediate-2/high IPSS risk myelodys-plastic syndromes: results in 83 patients from the Italian patient named program [abstract no. 0238 plus poster]. 13th Congress of the European Hematology Association; 2008 Jun 12-15; Copenhagen
44. Muller-Thomas C, Schuster T, Peschel C, et al. A limited number of 5-azacitidine cycles can be effective treatment in MDS. Ann Hematol 2009 Mar; 88 (3): 213-219
45. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000 Dec 1; 96 (12): 3671-3674
46. Mufti GJ, Fenaux P, Hellstrom-Lindberg E, et al. Treatment of high-risk MDS patients (pts) with -7/del(7q) with aza-citadine (AZA) versus conventional care regimens (CCR): effects on overall survival (OS) [abstract no. 7033 plus poster]. 44th Annual Meeting of the American Society of Clinical Oncology; 2008 May 30-Jun 3; Chicago (IL)
47. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival (OS) and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukemia compared with conventional care regimens [abstract no. 3636 plus poster]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6-9; San Francisco (CA)
48. Seymour JF, Fenaux P, Silverman LB, et al. Effects of azacitidine (AZA) vs conventional care regimens (CCR) in elderly (>75 years) patients (pts) with myelodysplastic syndromes (MDS) from the AZA-001 survival trial [abstract no. 3629]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6-9; San Francisco (CA)
49. Santini V, Fenaux P, Vey N, et al. European inter-country treatment selection differences do not alter overall survival benefit shown with azacitidine vs conventional care regimens in higher-risk myelodysplastic syndromes [abstract no. 0236 plus poster]. 13th Congress of the European Hematology Association; 2008 Jun 12-15; Copenhagen
50. Seymour J, Santini V, Fenaux P, et al. Effect of azacitidine (AZA) on transfusion independence (TI) and overall survival in patients (pts) with higher-risk myelodysplastic syndromes [abstract no. 0813 plus poster]. 14th Congress of the European Hematology Association; 2009 Jun 4-7; Berlin
51. List AF, Fenaux P, Mufti GJ, et al. Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission [abstract no. 7006]. J Clin Oncol 2008 May 20; 26 (15 Suppl.): 373s
52. Cheson BD, Greenberg PL, Bennett JM. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006 Jul 15; 108 (2): 419-425
53. Santini V, Fenaux P, Mufti GJ, et al. Management and supportive care measures of adverse events (AEs) in higher-risk MDS patients (pts) treated with azacitidine (AZA) [abstract no. 1653 plus poster]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6-9; San Francisco (CA)
54. Santini V, Fenaux P, Mufti GJ, et al. Patient outcome measures during prolonged survival in patients with high-risk myelodysplastic syndromes treated with azacitidine [abstract no. 7028 plus poster]. 44th Annual Meeting of the American Society of Clinical Oncology; 2008 May 30-Jun 3; Chicago (IL)
55. Celgene Corporation. Vidaza (azacitidine for injection) for SC or IV use: US prescribing information [online]. Available from URL: http://www.accessdata. fda.gov/drugsatfda- docs/label/2008/050794s011lbl.pdf [Accessed 2009 Jul 31]
56. Eisai Inc. Dacogen™ (decitabine for injection): US prescribing information [online]. Available from URL: http:// www.dacogen.com/hcp/ LinkedFiles/Prescribing-Information. pdf [Accessed 2009 Aug 11]
57. Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 2008 Apr; 49 (4): 690-695
58. Kantarjian H, Issa J-P, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006 Apr 15; 106 (8): 1794-1803
59. Wijermans P, Suciu S, Baila L, et al. Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC Leukemia and German MDS Study Groups [abstract no. 226]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6-9; San Francisco (CA)
60. Arber DA, Brunning RD, Orazi A, et al. Acute myeloid leukaemia with myelodysplasia-related changes. In: Swerdlow S, Campo E, Harris NL, et al, editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press, 2008: 124-126
61. Nordic MDS Group. Guidelines for the diagnosis and treatment of the myelodysplastic syndromes [online]. Available from URL: http://www.nmds.org/ez4/ index.php?/ nmds/Nordic-Care-Programme [Accessed 2009 Aug 20]
62. Feinberg B, Gilmore J, Haislip S, et al. Pharmacoeconomic evaluation of hypomethylating agents used for the treatment of MDS [abstract no. 2380]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6-9; San Francisco (CA)
63. Feinberg B, Scott J, Weidner S, et al. Budget impact model for hypomethylating agent use for the treatment of myelodysplastic syndromes (MDS) [abstract no. 2397]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6-9; San Francisco (CA)
64. Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009 Apr 10; 27 (11): 1850-1856
65. Martin MG, Walgren RA, Procknow E, et al. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. Am J Hematol 2009 Sep; 84 (9): 560-564
66. Field T, Perkins J, Huang Y, et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. Epub 2009 Jun 22
67. H. Lee Moffitt Cancer Center and Research Institute. Pre-transplant 5-azacitidine in patients with high-risk myelodysplastic syndrome (MDS) who are candidates for allogeneic hematopoietic cell transplant [ClinicalTrials.gov identifier NCT00660400]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Oct 14]
68. Virginia Commonwealth University. 5-Azacytidine prior to allogeneic stem cell transplant in high risk myelodysplastic syndrome [ClinicalTrials.gov identifier NCT00721214]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Oct 14]
69. Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: a New York Cancer Consortium [abstract no. 7000 plus slide presentation]. 44th Annual Meeting of the American Society of Clinical Oncology; 2008 May 30-Jun 3; Chicago (IL)
70. Voso MT, Santini V, Finelli C. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 2009 Aug 1; 15 (15): 5002-5007
71. Nand S, Godwin J, Smith S, et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma 2008 Nov; 49 (11): 2141-2147
72. Sekeres MA, List AF, Cuthbertson D, et al. Final results from a phase I combination study of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndomes (MDS) [abstract no. 221]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6-9; San Francisco (CA)